Caprion Pharmaceuticals announced this week the appointment of Marc Riviere to the position of Executive vice president of clinical development as of January 2005.
Dr. Riveire will have overall responsibility for clinical strategy, planning and execution, the company said. His initial mandate will be to lead the clinical development efforts of Caprion’s lead clinical program, an antibody therapy for the prevention of hemolytic uremic syndrome resulting from E. coli infection.
Prior to joining Caprion, Riviere served as chief medical officer for the Canadian biopharmaceutical company Bioniche Life Sciences. Before that, Riviere was vice president of clinical affairs for Aeterna Laboratories and executive vide president and regional director for Canada for Quintiles.
Charles River Laboratories said last week that Daniel Shaughnessy, senior vice president of corporate development, general counsel, and corporate secretary is leaving the company effective Dec. 31, to join the faculty of Northeastern University’s College of Business Administration. Jody Acford will replace Shaughnessy in these roles. Acford joins Charles River Laboratories from John Hancock Financial Services, where she served as senior vice president and deputy general counsel.
Applied Biosystems announced this week that Dennis Gilbert has been elected chief scientific officer and vice president of research for the company. In his role as CSO, Gilbert is responsible for leading ABI’s scientific and technical programs and coordinating cross-divisional research and development efforts.
Gilbert has more than 10 years of senior management experience at ABI’s parent corporation, Applera. Before being named CSO and vice president of research at ABI, he was vice president of genomic applications for ABI and vice president of gene discovery for Celera Genomics. Prior to that, he was program manager of genetics at W.R. Grace.
Â